Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company based in Menlo Park, CA, developing the AcuStream™ digitally connected electromechanical topical ocular delivery device. The AcuStream™ platform is multi-dose, preservative-free and aims to deliver topical ocular therapy reliably, accurately and comfortably while reducing reliance on patient skill and instillation technique. In phase 1 proof-of-concept studies the platform has shown potential for micro-dosing capability and a reduction in delivery dose of an intended therapy (up to an 80% reduction compared to standard eye drops, per company materials). Kedalion cites internal device focus groups, patient comfort testing and other data supporting the technology. The company plans to continue development of the AcuStream™ platform across multiple disease categories, drug classes and compositions, including the treatment of presbyopia. Kedalion recently completed a Series B financing and is collaborating with Novartis as an investor and partner. Kedalion Therapeutics is a venture-backed, clinical-stage biotech focused on developing and commercializing topical ophthalmology therapies based on its proprietary AcuStream platform. The AcuStream technology delivers topical drugs to the eye in a precise and accurate manner, enabling comparable therapeutic effect with up to an 80% reduction in dose compared to standard eye drops. The company intends to use new financing to advance the AcuStream platform through pilot-scale GMP manufacturing and to support advancement of its clinical programs. Management highlighted the platform's potential to improve patient comfort, convenience, compliance, and adherence with therapies, and to generate additional clinical data. Kedalion is based in Menlo Park, California.

Total raised

$5M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2018